Abstract: AIM: To explore the clinical efficacy of alprostadil injection treatment on reducing urinary protein and lowering blood viscosity of type 2 diabetic patients with diabetic nephropathy and the treatment efficacy changes over time.METHODS: 48 patients with type 2 diabetic were divided into two groups randomly. Both groups were given integrated treatment on chronic renal insufficiency, diabetic, high blood pressure, high blood sugar. The trial group was treated with alprostadil 10 μg/d for three weeks. The control group was given astragalus 30 mL/d intravenous infusion. The changes of urine albumin, blood viscosity and other clinical indicators were observed before and after the treatment and at the end of the 1,3,6,9,12th month.RESULTS: After treatment the urinary protein, blood viscosity of two groups were significantly decreased compared with those before treatment (P<0.05); The urinary protein of the experimental group was significantly lower than that of control group (P <0.05), but as time past that of, this gap decreased gradually. To the end of the 12 month there was no significant difference between them, and there was no significant difference at the end of the 9 month on the blood viscosity between the two groups.CONCLUSION: Patients with diabetic nephropathy who had received the treatment of alprostadil three weeks could decrease proteinuria excretion, lower blood viscosity but this protection for renal has some limitations in a long-term , the effect of treatment diminishes little by little in a year.

Key words: Diabetic nephropathy, Alprostadil, Hemorheology, Uric albumin